

## Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243
CIN: L24230TG1981PLC003201, www.natcopharma.co.in

November 3, 2017

Corporate Relationship Department M/s. BSE Ltd.
Dalal Sreet, Fort
Mumbai 400 001

Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) <u>Mumbai 400 051</u>

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed herewith the Press Release for your information.

Thanking you

Yours faithfully For NATCO Rharma Limited

M. Adinarayana

Company Secretary &

Vice President (Legal and Corp Affairs)

Encl: a.a



## Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.

Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243

CIN: L24230TG1981PLC003201, www.natcopharma.co.in

Ref:PR/12/2017

**Press Release** 

Hyderabad, 3<sup>rd</sup> November, 2017

Natco's marketing partner Alvogen first to market generic equivalent to oseltamivir phosphate powder for oral suspension in the USA

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that it's marketing partner Alvogen has received the final approval and is the first to market the generic equivalent to oseltamivir phosphate, 6 mg/ml powder for oral suspension in the United States. In December 2016, Alvogen launched the first generic equivalent to oseltamivir phosphate capsules in the United States.

Forwarded for favor of publication
For NATCO Pharma Limited

M. Adinarayana
Company Secretary &
Vice President (Legal and Corp Affairs)